bioRxiv · 10.1101/2024.04.17.589928
Spirolactone, an unprecedented antifungal β-lactone spiroketal macrolide from Streptomyces iranensis
Abstract
Fungal infections pose a great threat to public health and there are limited antifungal medicaments. Streptomyces is an important source of antibiotics, represented by the clinical drug amphotericin B. The rapamycin-producer Streptomyces iranensis harbors an unparalleled Type I polyketide synthase, which codes for a novel antifungal macrolide alligamycin A (1), the structure of which was confirmed by NMR, MS, and X-ray crystallography. Alligamycin A harbors an undescribed carbon skeleton with 13 chiral centers, featuring a ({beta}-lactone moiety, a [6,6]-spiroketal ring, and an unprecedented 7-oxo-octylmalonyl-CoA extender unit incorporated by a potential novel crotonyl-CoA carboxylase/reductase. The ali biosynthetic gene cluster was confirmed through CRISPR-based gene editing. Alligamycin A displayed profound antifungal effects against numerous clinically relevant filamentous fungi, including Talaromyces and Aspergillus species. ({beta}-Lactone ring is essential for the antifungal activity and alligamycin B (2) with disruption in the ring abolished the antifungal effect. Proteomics analysis revealed alligamycin A potentially disrupted the integrity of fungal cell walls and induced the expression of stress-response proteins in Aspergillus niger. Alligamycins represent a new class of potential drug candidate to combat fungal infections.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Yang, Z., Qiao, Y., Strobech, E., Morth, J. P., Walther, G., Jorgensen, T. S., Peschel, G., Rosenbaum, M. A., Previtali, V., Clausen, M. H., Lukassen, M. V., Gotfredsen, C. H., Kurzai, O., Ding, L.. 2024-04-17. Spirolactone, an unprecedented antifungal β-lactone spiroketal macrolide from Streptomyces iranensis. https://doi.org/10.1101/2024.04.17.589928
Cite the original work for its findings. Save a collection to share your selection of sources.